UA138919U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, the patient's serum determines the polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (β-β-β-β). With a homozygous carrier of 677-TT, 786-CC and endothelin levels> 10 ng / ml, folic acid <6 ng / ml, pyridinoline> 8 ng / ml, ΤΦΡ-β1 <14 ng / ml, PSA> 6 mg / l predict development of osteoarthritis.

Description

The proposed useful model, a method of predicting the development of osteoarthritis, belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

Сб677Т), nitric oxide synthase (6ЭМО5 1786С), content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (TGF-BI), C-reactive protein (CRP). With homozygous carriers of 677-HTT, 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline "8 ng/ml, TFR-VI "14 ng/ml, SRP "b mg/l predict the development osteoarthritis

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of endothelin, folic acid, pyridinoline, TFR-B1, SRP is determined by the immunoenzymatic method. With homozygous carrier 677-177, 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline 28 ng/ml, TFR-DI1 -14 ng/ml, PSA "6 mg/l predict the development of osteoarthritis .

A specific example of using the method.

Patient K., 56 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and eMmo5 17860 genes was determined in blood serum. The content of endothelin, folic acid, pyridinoline, TFR-VI, SRP was determined by immunoenzymatic method.

A homozygous carrier of 677-TT and 786-SS was established, the levels of endothelin - 22 ng/ml, folic acid - 3.6 ng/ml, pyridinoline - 16 ng/ml, TGF-B1-7.3 ng/ml, SRP - 15 mg/l The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (EMO5 1786С), the content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (TGF-DI1), C-reactive protein (CRP) and with homozygous carrier 677-TT, 786-SS and levels of endothelin "10 ng/ml, folic acid "6 ng/ml, pyridinoline "8 ng /ml, TFR-VI "14 ng/ml, PSA "6 mg/l predict the development of osteoarthritis.